Treatment
Medical Therapy
Medical therapy is indicated for patients who are unfit for surgery or who have an unresectable tumor. Jaundice and itching can be reduced with the placement of an endoprosthesis, either endoscopically or percutaneously, across strictures.
Endoscopic techniques for the relief of obstruction include sphincterotomy, balloon dilatation of the stricture, and the placement of stents.11 Larger, expandable metal stents, which have better patency rates than do plastic stents, include Metal-Palmaz, Strecker, Gianturco Z stent, and Wall stents.15
Percutaneous, transhepatic endoprosthetic insertion also is successful, but an increased risk of complications, such as blood and bile leakage, exists. Ninety percent of stents can be placed by a combination of endoscopic and percutaneous techniques after a failed endoscopic attempt.
Chemotherapy has been tried in these patients but has not been proven to be of definite benefit.16
Radiotherapy may be administered by external beam therapy; intraoperative radiotherapy using biliary stents with iridium (192 Ir), radium, or cobalt (60 Co); radioimmunotherapy using sodium iodide (131 I) anti-CEA as a component of therapy; or charged particle irradiation. Internal radiotherapy may be combined with biliary drainage, but the value is unproven.17,18
Pain may be relieved with the injection of 50% alcohol for chemical splanchnicectomy.
Surgical Therapy
Resection is the best treatment for bile duct tumors and provides the best palliation in terms of duration and freedom from infectious complications.19,20 Benefits of resection include the possibility of cure or long-term survival, especially for patients with distal tumors. The type of surgical procedure performed depends on the site and extent of the disease.
Proximal tumors (Klatskin tumors) may be managed by a variety of techniques, including the following:
- Patients with perihilar tumors (Bismuth classification I and II), without evidence of vascular invasion, are candidates for local excision. If achieving negative margins are not possible with local excision, resection of the corresponding lobe is indicated.
- Type III tumors are managed best by right or left hepatic lobectomy. Resection of the adjacent caudate lobe (segment I) may ensure adequate tumor-free margins in cases of involvement of the hepatic duct bifurcation.
- Sometimes, extended right or left hepatectomy and (rarely) central liver resection may need to be combined for adequate resection of the tumor.
Following resection of the bile duct, which may be combined with hepatic resection, reconstruction can be performed by unilateral or bilateral hepaticojejunostomy, using transhepatic stents.15
Surgical exploration is indicated in patients who are fit for surgery when preoperative evidence of metastases is absent or when locally unresectable disease exists. If metastases are detected at the time of surgical exploration, bilateral stents that may have been placed preoperatively are left in situ, and cholecystectomy is performed to prevent the subsequent development of acute cholecystitis. Locally advanced and unresectable perihilar tumors also can be managed by Roux-en-Y cholecysto(docho)jejunostomy with intraoperative placement of silastic biliary catheters or a segment III or V cholangiojejunostomy.
Mid-duct tumors can be managed using bile duct resection and Roux-en-Y reconstruction. Distal tumors may be amenable to Whipple resection (radical pancreaticoduodenectomy) (see first image below and Image 3) or pylorus-preserving pancreaticoduodenectomy. Unresectable tumors may be managed by cholecystectomy, a Roux-en-Y hepaticojejunostomy, or choledochojejunostomy proximal to the tumor, and additional gastrojejunostomy and chemical sympathectomy are considered.
Reconstruction involves anastomosis of bile ducts to a loop of jejunum (see second image below and Image 4).
Reconstruction after classic radical pancreaticoduodenectomy requires 3 anastomoses: pancreaticojejunostomy, choledochojejunostomy, and gastrojejunostomy. Illustration used with permission from Carol EH Scott-Conner, MD, PhD (ed), Chassin's Operative Strategy in General Surgery, Springer-Verlag, 2002.
Cholangiogram showing completed choledochojejunostomy with widely patent anastomosis.
Palliation
Surgical bypass is indicated in patients in whom placing a stent by either endoscopic or percutaneous techniques is impossible and in patients who are found to have unresectable disease or metastases at exploration.11
Bypass may be performed by either a Roux-en-Y hepaticojejunostomy with intraoperative placement of a silastic transhepatic stent or a segment III bypass to the left intrahepatic ducts. In patients with distal bile duct tumors, the operation of choice is biliary enteric bypass using the upper end of the extrahepatic bile duct or gallbladder. Consider prophylactic gastrojejunostomy in these patients, because some of these individuals may develop gastroduodenal obstruction prior to death. Bypass is less commonly required, because stents have improved, and even duodenal obstruction can now be effectively palliated.
Preoperative Details
Staging of the disease is determined by evaluating findings of CT scanning and MRI.6,7
Delineation of the tumor and its extent may be assessed by cholangiography (endoscopic and transhepatic) and magnetic resonance cholangiography.9
Vascular involvement can be identified and assessed by CT scan, MRI, and angiography, as previously described (see Imaging Studies).
Patient risk for surgery and anesthesia is determined, and cardiac and pulmonary assessment is performed.
If the clinical condition of the patient does not rule out surgical intervention, the resectability and extent of tumor involvement are assessed, and metastases are sought. Low and mid – bile duct tumors usually are resectable if angiography and venography exclude vascular invasion. Cancer of the hilar region tends to be less amenable to resection.
At surgery, further assessment is performed with intraoperative ultrasonographic scanning and a search for lymph node involvement.
Intraoperative Details
Laparoscopy in patients with bile duct tumors can be useful in the identification of metastases and peritoneal disease and, hence, may assist in assessing resectability.
Intraoperative ultrasonography also is useful and may be combined with laparoscopy.
Exploratory laparotomy is performed in patients who are fit for surgery and who are without any definite evidence of metastases or unresectability on preoperative investigation. One half of these patients are found to have evidence of intraperitoneal dissemination of the tumor or extensive involvement of the porta hepatis; therefore, they are candidates for minimal intervention, including bypass.
Postoperative Details
These patients are at risk for the development of general complications, including pneumonia, deep venous thrombosis, and infection. Routine perioperative antibiotic prophylaxis and coagulopathy are administered. Active physiotherapy, breathing exercises, and early ambulation are encouraged.
Complications specific to the procedure performed include anastomotic leak and bile leakage. Stents may be placed across anastomoses and removed after cholangiography confirms the absence or healing of leak.15
Follow-up
Patients who have evidence of positive tumor margins after resection or who develop recurrence may be candidates for adjuvant radiotherapy.17,18 This usually takes the form of extracorporeal therapy for positive surgical margins and intraluminal radiotherapy for positive duct margins. Chemotherapy has not been shown to be of benefit.16
Complications
Postoperative complications may be general or local. General complications include the following:
- Myocardial infarction (MI)
- Pneumonia
- Surgical site infection
- Deep venous thrombosis
- Pulmonary embolism (PE)
Technical complications related to the procedure performed include the following:
- Bile leak
- Stricture
- Postoperative hemorrhage
- Pancreatic fistula – May occur after radical pancreaticoduodenectomy
Complications arising from the placement of stents include the following:
- Early - Cholangitis (7%) and perforation
- Late - Blockage and migration of stent
More on Bile Duct Tumors |
| Overview: Bile Duct Tumors |
| Workup: Bile Duct Tumors |
 Treatment: Bile Duct Tumors |
| Follow-up: Bile Duct Tumors |
| Multimedia: Bile Duct Tumors |
| References |
| Further Reading |
| « Previous Page | Next Page » |
References
Smits NJ, Reeders JW. Imaging and staging of biliopancreatic malignancy: role of ultrasound. Ann Oncol. 1999;10 Suppl 4:20-4. [Medline].
Elfaki DH, Gossard AA, Lindor KD. Cholangiocarcinoma: expanding the spectrum of risk factors. J Gastrointest Cancer. Jan 14 2009;[Medline].
Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10 Suppl 4:308-11. [Medline].
Saurin JC, Joly-Pharaboz MO, Pernas P. Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures. Gut. Sep 2000;47(3):357-61. [Medline]. [Full Text].
Rijken AM, Offerhaus GJ, Polak MM. p53 expression as a prognostic determinant in resected distal bile duct carcinoma. Eur J Surg Oncol. Jun 1999;25(3):297-301. [Medline].
Freeny PC. Computed tomography in the diagnosis and staging of cholangiocarcinoma and pancreatic carcinoma. Ann Oncol. 1999;10 Suppl 4:12-7. [Medline].
Tani K, Kubota Y, Yamaguchi T. MR imaging of peripheral cholangiocarcinoma. J Comput Assist Tomogr. Nov-Dec 1991;15(6):975-8. [Medline].
Kim HJ, Lee JM, Kim SH, et al. Evaluation of the longitudinal tumor extent of bile duct cancer: value of adding gadolinium-enhanced dynamic imaging to unenhanced images and magnetic resonance cholangiography. J Comput Assist Tomogr. May-Jun 2007;31(3):469-74. [Medline].
Hanninen EL, Pech M, Jonas S, et al. Magnetic resonance imaging including magnetic resonance cholangiopancreatography for tumor localization and therapy planning in malignant hilar obstructions. Acta Radiol. Aug 2005;46(5):462-70. [Medline].
Sakai Y, Tsuyuguchi T, Tsuchiya S, et al. Clinical utility of peroral cholangioscopy for mucin-producing bile duct tumor. Hepatogastroenterology. Sep-Oct 2008;55(86-87):1509-12. [Medline].
Rumalla A, Baron TH. Evaluation and endoscopic palliation of cholangiocarcinoma. Management of cholangiocarcinoma. Dig Dis. 1999;17(4):194-200. [Medline].
Desa LA, Akosa AB, Lazzara S. Cytodiagnosis in the management of extrahepatic biliary stricture. Gut. Oct 1991;32(10):1188-91. [Medline]. [Full Text].
Furmanczyk PS, Grieco VS, Agoff SN. Biliary brush cytology and the detection of cholangiocarcinoma in primary sclerosing cholangitis: evaluation of specific cytomorphologic features and CA19-9 levels. Am J Clin Pathol. Sep 2005;124(3):355-60. [Medline].
Lamerz R. Role of tumour markers, cytogenetics. Ann Oncol. 1999;10 Suppl 4:145-9. [Medline].
Kawamoto H, Ishida E, Okamoto Y, et al. Evaluation of covered metallic stents in malignant biliary stenosis--prominent effectiveness in gallbladder carcinoma. Hepatogastroenterology. Sep-Oct 2005;52(65):1351-6. [Medline].
Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. Hepatogastroenterology. May-Jun 2000;47(33):644-9. [Medline].
Oh D, Lim do H, Heo JS, et al. The role of adjuvant radiotherapy in microscopic tumor control after extrahepatic bile duct cancer surgery. Am J Clin Oncol. Feb 2007;30(1):21-5. [Medline].
Pitt HA, Nakeeb A, Abrams RA. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg. Jun 1995;221(6):788-97; discussion 797-8. [Medline]. [Full Text].
Kosuge T, Yamamoto J, Shimada K. Improved surgical results for hilar cholangiocarcinoma with procedures including major hepatic resection. Ann Surg. Nov 1999;230(5):663-71. [Medline]. [Full Text].
Havlik R, Sbisa E, Tullo A. Results of resection for hilar cholangiocarcinoma with analysis of prognostic factors. Hepatogastroenterology. Jul-Aug 2000;47(34):927-31. [Medline].
Ferrero A, Lo Tesoriere R, Vigano L, et al. Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. World J Surg. Feb 2009;33(2):318-25. [Medline].
Gerhards MF, Gonzalez DG, ten Hoopen-Neumann H. Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy. Eur J Surg Oncol. Aug 2000;26(5):480-5. [Medline].
Ortner MA. Photodynamic therapy of cholangiocarcinoma cancer. Gastrointest Endosc Clin N Am. Jul 2000;10(3):481-6. [Medline].
Jeyarajah DR, Klintmalm GB. Is liver transplantation indicated for cholangiocarcinoma?. J Hepatobiliary Pancreat Surg. 1998;5(1):48-51. [Medline].
Burke EC, Jarnagin WR, Hochwald SN. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg. Sep 1998;228(3):385-94. [Medline]. [Full Text].
Chamberlain RS, Blumgart LH. Hilar cholangiocarcinoma: a review and commentary. Ann Surg Oncol. Jan-Feb 2000;7(1):55-66. [Medline]. [Full Text].
Chan C, Medina-Franco H, Bell W. Carcinoid tumor of the hepatic duct presenting as a Klatskin tumor in an adolescent and review of world literature. Hepatogastroenterology. Mar-Apr 2000;47(32):519-21. [Medline].
Chen MF. Peripheral cholangiocarcinoma (cholangiocellular carcinoma): clinical features, diagnosis and treatment. J Gastroenterol Hepatol. Dec 1999;14(12):1144-9. [Medline].
Fan ZM, Yamashita Y, Harada M. Intrahepatic cholangiocarcinoma: spin-echo and contrast-enhanced dynamic MR imaging. AJR Am J Roentgenol. Aug 1993;161(2):313-7. [Medline]. [Full Text].
Hanack U, Lorf T, Binder L. Surgical treatment of cholangiocellular carcinoma. Swiss Surg. 1999;5(3):111-5. [Medline].
Jarnagin WR. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol. Sep-Oct 2000;19(2):156-76. [Medline].
Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. Oct 8 2005;366(9493):1303-14. [Medline].
Kimura Y, Nishikawa N, Okita K, et al. Biliary tract malignancy and chronic inflammation from the perspective of pancreaticobiliary maljunction. Oncology. 2005;69 Suppl 1:41-5. [Medline].
Lee SG, Lee YJ, Park KM. One hundred and eleven liver resections for hilar bile duct cancer. J Hepatobiliary Pancreat Surg. 2000;7(2):135-41. [Medline].
Marcos-Alvarez A, Jenkins RL. Cholangiocarcinoma. Surg Oncol Clin N Am. Apr 1996;5(2):301-16. [Medline].
Martin RF, Rossi RL. Multidisciplinary considerations for patients with cancer of the pancreas or biliary tract. Surg Clin North Am. Apr 2000;80(2):709-28. [Medline].
Neuhaus P, Jonas S. Surgery for hilar cholangiocarcinoma--the German experience. J Hepatobiliary Pancreat Surg. 2000;7(2):142-7. [Medline].
Schmassmann A. Nonsurgical therapies for hepatocellular and cholangiocellular carcinoma. Swiss Surg. 1999;5(3):116-21. [Medline].
Shuangshoti S Jr, Shuangshoti S. Primary mucoepidermoid carcinoma of the intrahepatic bile duct: a case report with review of literature. J Med Assoc Thai. Feb 2000;83(2):197-203. [Medline].
Zervos EE, Osborne D, Goldin SB, et al. Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg. Nov 2005;190(5):810-5.
Further Reading
Related eMedicine topics:
Biliary Disease
Biliary Cystadenoma/Cystadenocarcinoma
Bile Duct Strictures
Biliary Obstruction
Cholangiocarcinoma [Oncology]
Cholangiocarcinoma [Radiology]
Gallbladder, Carcinoma
Gallbladder Tumors
Hepatic Adenoma
Percutaneous Gastrostomy and Jejunostomy
Postcholecystectomy Syndrome
Keywords
bile duct tumors, bile, bile duct, liver, pancreas, pancreatic, gall bladder, gallbladder, biliary, hepatic, cholecystectomy, cholangiocarcinoma, bile duct cancer, liver bile, biliary tree, biliary duct, biliary disease, gall bladder disease, gallbladder disease, gall bladder cancer, gallbladder cancer, bile duct symptoms, bile ducts, Klatskin tumor, cholangiocarcinoma of the hepatic duct bifurcation
